| A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis (NCT06723535) | Bristol-Myers Squibb | 2024-12-07 |
| Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer (NCT06499298) | Bristol-Myers Squibb | 2024-12-03 |
| A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes (NCT06581055) | Bristol-Myers Squibb | 2024-11-30 |
| Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database (NCT07079644) | Bristol-Myers Squibb | 2024-11-29 |
| Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments (NCT06448793) | Bristol-Myers Squibb | 2024-11-25 |
| A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept (NCT06971185) | Bristol-Myers Squibb | 2024-11-22 |
| Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1% (NCT07215962) | Bristol-Myers Squibb | 2024-11-22 |
| A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept (NCT07075406) | Bristol-Myers Squibb | 2024-11-01 |
| Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy (NCT07024862) | Bristol-Myers Squibb | 2024-10-24 |
| A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors (NCT06544655) | Bristol-Myers Squibb | 2024-10-10 |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (NCT06561386) | Bristol-Myers Squibb | 2024-10-07 |
| A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants (NCT06568458) | Bristol-Myers Squibb | 2024-09-19 |
| A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea (NCT06698887) | Bristol-Myers Squibb | 2024-09-11 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. (NCT06476808) | Bristol-Myers Squibb | 2024-09-06 |
| Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France (NCT06735781) | Bristol-Myers Squibb | 2024-09-05 |
| Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants (NCT06577259) | Bristol-Myers Squibb | 2024-09-03 |
| A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants (NCT06493409) | Bristol-Myers Squibb | 2024-08-26 |
| A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States (NCT06851065) | Bristol-Myers Squibb | 2024-08-22 |
| A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan (NCT06596642) | Bristol-Myers Squibb | 2024-08-21 |
| Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea (NCT06258668) | Bristol-Myers Squibb | 2024-08-21 |
| A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring (NCT06710470) | Bristol-Myers Squibb | 2024-08-02 |
| A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease (NCT06481306) | Bristol-Myers Squibb | 2024-07-17 |
| A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies (NCT05209295) | Bristol-Myers Squibb | 2024-07-12 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants (NCT06476821) | Bristol-Myers Squibb | 2024-06-27 |
| A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants (NCT06476834) | Bristol-Myers Squibb | 2024-06-24 |
| Real-World Effectiveness of Mavacamten in Canada (NCT06338202) | Bristol-Myers Squibb | 2024-06-24 |
| Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment (NCT06425198) | Bristol-Myers Squibb | 2024-06-10 |
| Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT06419634) | Bristol-Myers Squibb | 2024-05-29 |
| A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis (NCT06396039) | Bristol-Myers Squibb | 2024-05-15 |
| Real-world Patient Reported Outcomes Among Patients Treated With Camzyos (NCT06551129) | Bristol-Myers Squibb | 2024-05-10 |
| A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment (NCT06352528) | Bristol-Myers Squibb | 2024-04-29 |
| A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada (NCT06549608) | Bristol-Myers Squibb | 2024-04-20 |
| A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea (NCT06073873) | Bristol-Myers Squibb | 2024-04-19 |
| A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy (NCT06253221) | Bristol-Myers Squibb | 2024-04-17 |
| Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy (NCT06422247) | Bristol-Myers Squibb | 2024-04-05 |
| A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia (NCT06073860) | Bristol-Myers Squibb | 2024-03-25 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (NCT06268886) | Bristol-Myers Squibb | 2024-03-20 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis (NCT06248814) | Bristol-Myers Squibb | 2024-03-06 |
| A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer (NCT06452329) | Bristol-Myers Squibb | 2024-02-28 |
| Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients (NCT06345183) | Bristol-Myers Squibb | 2024-02-19 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants (NCT06144697) | Bristol-Myers Squibb | 2024-01-29 |
| A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy (NCT06112743) | Bristol-Myers Squibb | 2024-01-24 |
| A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) (NCT06382987) | Bristol-Myers Squibb | 2024-01-22 |
| A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants (NCT06211179) | Bristol-Myers Squibb | 2024-01-10 |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas (NCT06090539) | Bristol-Myers Squibb | 2023-12-29 |
| A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US (NCT07107373) | Bristol-Myers Squibb | 2023-12-22 |
| Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in Japan (NCT06298643) | Bristol-Myers Squibb | 2023-12-22 |
| A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan (NCT06163040) | Bristol-Myers Squibb | 2023-12-22 |
| A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) (NCT06140836) | Bristol-Myers Squibb | 2023-12-21 |
| A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan (NCT06181617) | Bristol-Myers Squibb | 2023-12-06 |
| DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation (NCT05838781) | Bristol-Myers Squibb | 2023-12-04 |
| COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) (NCT06372457) | Bristol-Myers Squibb | 2023-12-01 |
| An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany (NCT06169956) | Bristol-Myers Squibb | 2023-11-30 |
| A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (NCT06094296) | Bristol-Myers Squibb | 2023-11-27 |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (NCT06035497) | Bristol-Myers Squibb | 2023-11-20 |
| A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants (NCT06086886) | Bristol-Myers Squibb | 2023-11-16 |
| A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia (NCT07681440) | Bristol-Myers Squibb | 2023-11-16 |
| A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia (NCT06073769) | Bristol-Myers Squibb | 2023-11-15 |
| Mavacamten Pregnancy Surveillance Program (NCT05939700) | Bristol-Myers Squibb | 2023-11-09 |
| A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors (NCT06024174) | Bristol-Myers Squibb | 2023-11-09 |
| Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (NCT06122779) | Bristol-Myers Squibb | 2023-11-07 |
| A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations (NCT06101134) | Bristol-Myers Squibb | 2023-11-06 |
| A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer (NCT06067841) | Bristol-Myers Squibb | 2023-10-18 |
| A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity (NCT06084598) | Bristol-Myers Squibb | 2023-10-12 |
| A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis (NCT06042920) | Bristol-Myers Squibb | 2023-10-09 |
| A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants (NCT06045689) | Bristol-Myers Squibb | 2023-10-05 |
| A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult Participants (NCT06034899) | Bristol-Myers Squibb | 2023-09-22 |
| A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus (NCT06013995) | Bristol-Myers Squibb | 2023-09-21 |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome (NCT05946941) | Bristol-Myers Squibb | 2023-09-11 |
| Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada (NCT06361576) | Bristol-Myers Squibb | 2023-09-05 |
| A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants (NCT06027437) | Bristol-Myers Squibb | 2023-09-05 |
| Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada (NCT06361563) | Bristol-Myers Squibb | 2023-09-05 |
| A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home (NCT06163053) | Bristol-Myers Squibb | 2023-08-29 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy (NCT05470985) | Bristol-Myers Squibb | 2023-08-22 |
| A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants (NCT05981976) | Bristol-Myers Squibb | 2023-08-18 |
| A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants (NCT05985590) | Bristol-Myers Squibb | 2023-08-18 |
| A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants (NCT05981963) | Bristol-Myers Squibb | 2023-08-17 |
| A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure (NCT05952089) | Bristol-Myers Squibb | 2023-08-17 |
| A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants (NCT05963932) | Bristol-Myers Squibb | 2023-08-08 |
| A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (NCT05658601) | Bristol-Myers Squibb | 2023-07-14 |
| A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants (NCT05932303) | Bristol-Myers Squibb | 2023-07-12 |
| A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants (NCT05866627) | Bristol-Myers Squibb | 2023-07-04 |
| A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants (NCT05932277) | Bristol-Myers Squibb | 2023-06-29 |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma (NCT05827016) | Bristol-Myers Squibb | 2023-06-22 |
| A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam (NCT05901714) | Bristol-Myers Squibb | 2023-06-14 |
| A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants (NCT05811416) | Bristol-Myers Squibb | 2023-06-14 |
| A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis (NCT06073847) | Bristol-Myers Squibb | 2023-06-13 |
| A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors (NCT05888831) | Bristol-Myers Squibb | 2023-06-06 |
| A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants (NCT05891262) | Bristol-Myers Squibb | 2023-06-06 |
| A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India (NCT05891249) | Bristol-Myers Squibb | 2023-06-05 |
| A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants (NCT05852769) | Bristol-Myers Squibb | 2023-05-31 |
| A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder (NCT05742867) | Bristol-Myers Squibb | 2023-05-31 |
| A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer (NCT05496192) | Bristol-Myers Squibb | 2023-05-31 |
| Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France (NCT06565975) | Bristol-Myers Squibb | 2023-05-23 |
| A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants (NCT05899738) | Bristol-Myers Squibb | 2023-05-18 |
| A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants (NCT05847439) | Bristol-Myers Squibb | 2023-05-05 |
| A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany (NCT06104644) | Bristol-Myers Squibb | 2023-04-13 |
| A Rollover Study of CC-122 (NCT05688475) | Bristol-Myers Squibb | 2023-04-11 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants (NCT05813717) | Bristol-Myers Squibb | 2023-04-10 |
| A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis (NCT05730725) | Bristol-Myers Squibb | 2023-04-03 |